Johnson & Johnson
Johnson & Johnson Reports Strong 2023 Financial Results and Key Regulatory Approvals
Summary
Johnson & Johnson announced robust financial results for Q4 and full-year 2023, reporting a 7.3% increase in sales to $21.4 billion and a 39.3% rise in earnings per share (EPS) to $1.70 for the quarter. The company's full-year sales reached $85.2 billion, with a 15.3% decrease in EPS to $5.20 due to a special one-time charge in Q1. Additionally, Johnson & Johnson secured several regulatory approvals, including full FDA approval for BALVERSA to treat bladder cancer and VARIPULSE Pulsed Field Ablation platform approval in Japan.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement